Latest news

Our press releases and latest news

Here you will always find the latest news about Cannamedical® Pharma.

MEDIACONTACT US







Cologne, September 9th, 2019 – On September 9th, Cannamedical® Pharma GmbH, a leading cannabis distributor and one of the best-known medicinal cannabis brands in Germany and the European Union, imported from Portugal to Germany, the largest quantity of medicinal cannabis ever transported within the European Union.

“The European market is clearly developing its ability to grow and ship world-class medicinal cannabis products, which is an important step in the development of the EU medicinal cannabis market, which we believe will be the world’s largest. Cannamedical continues to demonstrate that our approach as the leading independent importer of finding the best products in all supply markets to serve to our patients can establish milestones within the industry,” says David Henn, CEO of Cannamedical. “We are proud of the contribution we are making to provide a stable supply of medicinal cannabis to patients in Germany and thankful for our world-class supply partners.”

Once the packaging process is complete, the imported Cannamedical product is expected to be available to patients beginning in mid-October. Cannamedical continues to be the only independent medicinal cannabis importer to successfully distribute products under its own brand name in Germany.

With this import, Cannamedical continues to expand its global network of suppliers within the cannabis industry. Cannamedical announced in May 2019 that it had entered into three international supply agreements with suppliers of medicinal cannabis flowers and extracts and has since initiated two additional EU-GMP certifications for supplier partners. The company currently holds a total of 9 supply agreements with partners across three continents.

Cannamedical Pharma GmbH is the largest independent importer and distributor of medicinal cannabis in Germany. Cannamedical was founded by David Henn in November 2016 and its 50+ employees are based in Cologne. In early 2019, Cannamedical raised €15M from New York and Hamburg-based investment firm Orkila Capital. The company recently expanded its management team with the addition of Chief Commercial Officer, Dr. Thomas Baur and Head of Quality Assurance, Dr. Ralf Bradenahl.

Press contact

Sandra Grußbach
E-Mail: presse@cannamedical.de
Phone: +49 221 999 852 51

About Cannamedical® Pharma GmbH

We at Cannamedical® Pharma GmbH are committed to helping doctors, medical specialists and pharmacists to improve their patients’ quality of life. The top-class products by Cannamedical concentrate on helping people with chronic illnesses to lead the best possible life with medicinal cannabis. To this end, we import and process only high-quality medicinal cannabis products and supply them to around 2,500 pharmacies and clinical facilities.
As well as the provision of top-class medicinal cannabis products, our focus is on training medical professionals, and providing sector-leading customer service. Our production partners worldwide must comply with the highest pharmaceutical quality standards – the so-called GMP guidelines (Good Manufacturing Practice). With its quality management, Cannamedical guarantees the highest product standards. We ourselves are GDP-certified (Good Distribution Practice), in other words, our entire supply chain is guaranteed, from the agricultural environment to the pharmacy. Cannamedical® Pharma GmbH was founded in Cologne in 2016 and employs more than 50 staff. In addition, Cannamedical operates subsidiaries in Canada and the UK.

For more information, visit www.cannamedical.com.

Photo David Henn, CEO Cannamedical® Pharma GmbH available at:
https://cannamedical.de/foto-david-henn

Photo of the shipment available at:
https://cannamedical.de/foto_import_charterflug



Cologne, 4 September 2019 – Cannamedical® Pharma GmbH, one of the best-known medicinal cannabis companies in Germany and the European Union, is expanding its management team with experienced experts from the pharmaceutical industry. The independent importer and wholesaler has named Dr. med. Thomas Baur as Chief Commercial Officer (CCO). With immediate effect, the 41-year-old will be responsible for the areas of Medical Affairs, Marketing, Pharmacy and Field Sales, with a focus on providing professional advice and support to doctors, pharmacies and health insurers, as well as the expansion of the sales network.

“In Dr. Thomas Baur we have decided to employ one top expert. With his experience and industry knowledge we will strengthen our quality assurance and the expansion of the Cannamedical brand. Together we shall continue to extend our advantage as the largest and best-known independent importer of medicinal cannabis, and secure our success in Germany and the EU in the long term,” says David Henn, CEO and founder of Cannamedical.

For the last 15 years, Baur has held management positions in healthcare companies such as Fresenius, Medtronic and Grünenthal, specialising in pain therapy. Most recently, Baur’s responsibilities included commercial assessment and business development, and he was head of the business unit for the hospital business in the DACH region.

“I am delighted to be part of the Cannamedical team. Cannamedical already offers leading products and services to physicians and pharmacists, in order to enable patients to lead a life worth living. Our clear objective is to further extend our leading position in the market, and to redefine the quality of consultation provided to doctors, pharmacies and health insurers. Together we want to adapt new approaches to treatment and provide innovative therapy options in the form of medicinal cannabis to patients with various illnesses,” says Dr. Thomas Baur, CCO Cannamedical.

Founded in November 2016 by David Henn, Cannamedical is now the largest independent importer and wholesaler of medicinal cannabis in Germany. Based in Cologne, since commencing operations in 2017, Cannamedical now has more than 50 employees.

Press contact

Sandra Grußbach
E-Mail: presse@cannamedical.de
Phone: +49 221 999 852 51

About Cannamedical® Pharma GmbH

We at Cannamedical® Pharma GmbH are committed to helping doctors, medical specialists and pharmacists to improve their patients’ quality of life. The top-class products by Cannamedical concentrate on helping people with chronic illnesses to lead the best possible life with medicinal cannabis. To this end, we import and process only high-quality medicinal cannabis products and supply them to around 2,500 pharmacies and clinical facilities.
As well as the provision of top-class medicinal cannabis products, our focus is on training medical professionals, and providing sector-leading customer service. Our production partners worldwide must comply with the highest pharmaceutical quality standards – the so-called GMP guidelines (Good Manufacturing Practice). With its quality management, Cannamedical guarantees the highest product standards. We ourselves are GDP-certified (Good Distribution Practice), in other words, our entire supply chain is guaranteed, from the agricultural environment to the pharmacy. Cannamedical® Pharma GmbH was founded in Cologne in 2016 and employs more than 50 staff. In addition, Cannamedical operates subsidiaries in Canada and the UK.

For more information, visit www.cannamedical.com.

Photo of Dr. med. Thomas Baur at: https://cannamedical.de/foto-thomas-baur/

Photo of Dr. rer. nat. Ralf Bradenahl at: https://cannamedical.de/foto-ralf-bradenahl/

Photo of David Henn, CEO Cannamedical® Pharma GmbH at: https://cannamedical.de/foto-david-henn/



Cologne, Germany, 29 January 2019 – Cannamedical® Pharma GmbH, one of the leading independent cannabis wholesalers in Germany and the European Union, has received a 15-million-euro equity investment from the US- and Germany-based growth equity investment firm Orkila Capital LLC. As a result of its investment, Orkila Capital has acquired a minority in Cannamedical.

“I am very pleased that Orkila Capital has recognized our growth potential and chosen to invest in us. Our most important goal is to ensure the timely supply of medicinal cannabis to patients at all times. And we are very proud of our reputation in Germany for providing the highest levels of customer service and operating with transparency and integrity. Today we help doctors, healthcare professionals and pharmacists in Germany and other European countries to improve the quality of their patients’ lives. Our products are focused on helping people with cancer, multiple sclerosis (MS) and chronic or acute pain to live their best life with medical cannabis” commented David Henn, CEO and founder of Cannamedical® Pharma GmbH.

Cannamedical®’s commitment is aimed at safety, reliability and a quality management system that guarantees the highest possible product standards. All production partners must also meet the highest pharmaceutical quality standards worldwide – the so-called GMP guidelines (Good Manufacturing Practice).

Jesse Du Bey, founder and Managing Partner of Orkila Capital, says: “We look for leading platforms in massive and evolving consumer markets and have found such an opportunity in Cannamedical®. As with our early leading investments in the global health and wellness space and the European craft beer industry, we believe in Cannamedical®’s ability to provide customers with an innovate product and help develop the potential of a huge market. Having observed the development of the North American medical cannabis market, we know medical cannabis is an important, organic medicine with few side effects, primarily targeting patients with acute and chronic conditions. Having witnessed the terrible consequences of the opiate prescription wave in the US, we believe Cannamedical® can be a key player in helping German healthcare professionals provide millions of consumers with a natural therapy for chronic pain and many other acute conditions.”

Orkila Capital’s Series A investment in Cannamedical® is the largest private equity transaction in the cannabis industry in Europe. Following Orkila Capital’s investment, founder David Henn holds approximately 60 percent of the shares in Cannamedical® Pharma GmbH. SN-Invests, a Luxembourg-based start-up investor, is the company’s third largest shareholder with a stake of almost 21 percent.

Currently, around 60,000 patients in Germany have a license to use medical cannabis. Independent research and comparison with data from other countries shows that up to three percent of the population could benefit from treatment with medicinal cannabis, which could equate to up to approximately 2.5 million patients in Germany. For the EU as a whole, the patient population could eventually equate to approximately 15 million patients.

Cannamedical® Pharma GmbH was founded in 2016 and started operating following the legalization of medical cannabis in Germany in March 2017. Today, the Company employs around 40 employees in Cologne and generates a million turnover.

Press contact
Kristina Quade
Email: presse[at]cannamedical.de
Phone: +49 221 999 852 57

About Cannamedical® Pharma GmbH

We at Cannamedical® Pharma GmbH are committed to helping doctors, healthcare professionals and pharmacists to improve the quality of their patients’ lives. Cannamedical®’s products are focused on helping people with cancer, multiple sclerosis (MS) and chronic or acute pain to live their best life with medical cannabis. To this end, we import high-quality medical cannabis products and distribute them to around 2,000 pharmacies and clinical facilities.
In addition to the medical care of patients, our focus is on education within the professional framework and the satisfaction of our customers. Our commitment is aimed at safety, reliability and a quality management system that guarantees the highest possible product standards. Our production partners must also meet the highest pharmaceutical quality standards worldwide – the so-called GMP guidelines (Good Manufacturing Practice). We ourselves are GDP (Good Distribution Practice) certified, meaning that our products are of the highest quality during manufacture and our entire supply chain is guaranteed, right up to the pharmacy delivery. Cannamedical® Pharma GmbH was founded in 2016 and employs around 40 people in Cologne. Cannamedical also has subsidiaries in Canada, the United Kingdom and Greece.
For more information visit cannamedical.com.

About Orkila Capital LLC

Orkila Capital LLC (“Orkila”) was formed in 2013 to pursue proprietary and compelling growth equity investment opportunities in the consumer, media and entertainment sectors.
Orkila invests in leading companies at the forefront of evolving market opportunities, including Mikkeller, Recognition Media (The Webby Awards), Omnipollo and Bellator MMA. Additionally, the Principals of Orkila co-founded Crash Line Productions (Boston Calling Music Festival) as well as sourced and helped execute the IRONMAN investment on behalf of their prior firm.
With over 20 years of experience, the principals of Orkila seek to leverage their deep industry knowledge and relationships to focus on growth platforms with differentiated brands, IP, assets or content. Orkila manages approximately $200 million of capital across two private equity funds.
For more information visit orkilacapital.com.


Stellio-Arzt60-1200x675.jpg

Cologne  –  Cannamedical® Pharma GmbH has successfully imported the first two batches of homogeneous MedReleaf varieties to Germany. Cannamedical® is now selling one of the high-quality cannabis strains to pharmacies throughout Germany. Six other varieties will become available in the coming weeks.

“With the first successful import from Canada at the beginning of July 2018, Cannamedical® Pharma laid the foundation for a quality-oriented and nationwide supply of European patients,” explains Niklas Kouparanis, Sales Director of the Cologne-based company. “We see a steadily growing demand in our pharmacy network since the introduction of the cannabis law in Germany in March 2017.

The number of cannabis units dispensed by prescription throughout Germany, has increased almost fifty times since the first quarter of 2017 to the first quarter of 2018. The fact that we will continue to import extraordinarily large quantities of standardized medical cannabis to Europe is greatly added value, in particular for patients, but also for pharmacists & doctors and underlines the company’s high level of professionalism as an established wholesaler. ”

Transparency, trust and reliability are among the core values of Cannamedical® Pharma. As a special service, and a first in Germany, doctors and pharmacists now have the opportunity to obtain information about the respective cannabinoid and terpene profile for each MedReleaf variety from the Cologne based wholesaler

“Terpenes have been underestimated for a long time. Today, however, one can assume that they play an essential part in the medical mode of action and are therefore of great importance for the therapy recommendation, “explains Katrin Rinas, Medical Advisor at Cannamedical®.

MedReleaf is one of the few GMP and ISO 9001 certified cannabis manufacturers in North America that is able to produce continuous homogeneous cannabis varieties.

The cooperation of both companies ensures product of the highest quality combined with a comprehensive range of services. The supply agreement with the Canadian producer represents a decisive step for Cannamedical® towards a permanent and nationwide supply of medicinal cannabis. The standardized MedReleaf varieties have stable genetics and are distributed throughout Germany  exclusively by Cannamedical® Pharma GmbH.

David Henn, CEO of Cannamedical® Pharma, emphasizes, “With the successful import from Canada and the support we provided with MedReleaf’s GMP certification, we are definitely among the most influential medical cannabis wholesalers in Europe. We are constantly expanding this leading position within Europe, “says the managing director.

“We are in an ideal position to reliably supply new European markets that are opening up in the near future.”

Medical experts can get comprehensive advice from Monday to Friday from 8 am to 8 pm from the expert team of Cannamedical® Pharma GmbH.

Cannamedical®-Pharmacy Advice line: +49 (0) 221 / 999 852 – 25

Cannamedical®-Doctors Advice line: +49 (0) 221 / 999 852 – 60

 


iStock-864453872_news.jpg

MedReleaf Corp. (TSX:LEAF) (“MedReleaf” or the “Company”), Canada’s first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has entered into an agreement to become the largest supplier of medical cannabis products to Cannamedical Pharma GMBH (“Cannamedical”), a leading medical cannabis distributor to pharmacies in Germany. MedReleaf will provide Cannamedical with monthly exports of five of its premium strain varieties significantly improving the predictability and security of drug delivery to the German market. Sales to Germany will commence promptly upon the expected receipt of MedReleaf’s European Medical Agency Good Manufacturing Practices (“GMP”) certification and export permit from Health Canada in the coming weeks.

Germany is poised to become the largest federally regulated medical cannabis market in the world, with a population of over 82 million, approximately 89% of whom are covered by the public health insurance program and the remainder covered by private insurance plans. The current medical cannabis laws in Germany came into effect on March 10, 2017 and without domestic production, cannabis is being imported to meet the rapidly growing demand.

“Federally legal markets for cannabis outside Canada are by and large focused on medical applications. This plays to MedReleaf’s core strengths in R&D, innovation, quality control, and pharmaceutical grade standards,” said Neil Closner, President and CEO. “Medical cannabis in Germany has been in short supply and Cannamedical is an ideal partner to bring MedReleaf’s premium cannabis products into Germany as one of Europe’s leading cannabis distributors with shared values on patient-centricity, a proven track record, and a growing network of 1,800 pharmacies.”

“We are very much looking forward to supply all patients in need of medication with premium quality cannabis produced by the leading Canadian cannabis producer. Both companies have grown in a strong and excellent partnership to implement all German GMP standards in close collaboration.” said David Henn, CEO.

About MedReleaf Corp.

Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 90001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf

About Cannamedical

Pioneering in the German cannabis industry, Cannamedical has been one of the first to specialize in highly efficient pharma distribution and marketing in accordance with the narcotics regulations. The privately-owned, GDP certified company holds all licenses required for medical cannabis import to Germany, distribution and export within the European Union. Cannamedical, as independent wholesaler has expertise in cannabis products and is serving an established and growing network of pharmacies all around the country.


berlin-1319648_60.jpg

On March 10th, 2018, the law “Cannabis as medicine” celebrates its first anniversary. For thousands of patients, the new law is a blessing. Thanks to the new law they benefit from the cannabis therapies which have to be paid by their health insurance companies. But not only from a health point of view does the cannabis law function like a European guidepost. A German company stands up for patients and is striving to ensure the European supply in the future.

The federal government had the courage to allow cannabis as medicine in Europe. Now it’s turning into a huge industry that will generate hundreds of new jobs and millions of euros in tax revenue in the near future.

At Cannamedical® Pharma GmbH, Germany´s leading independent cannabis wholesaler, 35 new permanent jobs were created for Cologne since the amendment of the law 12 months ago. And the potential is far from being exhausted. “We expect to create more than 350 new jobs within the next 24 months,” predicts David Henn, CEO of Cannamedical®

The independent wholesaler, based in Cologne, not only promotes better healthcare throughout Europe, but also offers innovative solutions to physicians and patients. Recently, Cannamedical® has entered a long-term partnership with one of Canada’s largest cannabis producers. “This partnership enables us to introduce up to 22 tons of high-quality cannabis to the European market by 2018,” says Niklas Kouparanis, the Sales Director of the company.

Last but not least, being based in Cologne is immensely important to Cannamedical® because of its cooperative supervisory authorities. The ongoing growth plans and the development of new sales markets could mean millions of euros for the city of Cologne in terms of tax revenues in the coming years.

Cannamedical® strives to strengthen the excellent cooperation between health insurance companies, importers and politicians in order to help Germany remain an internationally competitive business location and to improve the national job market.

“We are constantly reviewing production sites as we are looking to invest up to €20 million in a GMP-compliant, state-of-the-art manufacturing facility in the first expansion phase. In addition, Cannamedical® will invest another 10 million euros in cannabis research together with international partners over the next three years.

A large number of European countries have already created very attractive and inviting framework conditions for this, and another German location with comparable conditions could also be exciting. We are convinced that the cannabis agency will soon reach a decision regarding their public announcement on cannabis production from June 2017 and follow the example set by other European neighbors, “says Henn.

Download PDF






We’re here to help

Contact us

Enjoy the benefits of our 360-degree all-round service.

PHONE

Mo. – Fr. 8am-6pm
+49 221 999 96 – 0



MAIL

ANYTIME
info@cannamedical.com



We are member of the DGS, BPC and VCI

Membership



Follow us

Social media

We are active on the
following platforms.


Ihr Warenkorb

CANNAMEDICAL
Vollspektrum-Extrakt

Jetzt neu: Entdecken Sie die Innovation des Jahres!

      Einzigartig in Deutschland

      Wirkungsvoll

     Einfache & diskrete Handhabung

      Höchste Qualität

 

Möchten Sie mehr erfahren? Ärzte und Apotheker können Sie zu unserem neuen Produkt beraten!


Abbildung entspricht nicht dem Original.

Hotline für Ärzte
0221 999 96 – 160

Hotline für Apotheker
0221 999 96 – 125

Beratung, wann immer es Ihnen passt: Einfach Termin auswählen und wir rufen Sie zu der von Ihnen gewünschten Zeit an!

Unser Expertenteam steht Ihnen von Mo.–Fr. zwischen 8 und 18 Uhr zur Verfügung.

Fachgruppe
Datum
Uhrzeit

Datenschutz*
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.